

## Special Issue

# Novel Targeted Therapies for T-cell Malignancies

### Message from the Guest Editor

T-cell malignancies are a broad range of disorders characterized by the clonal proliferation of T cells arrested at different developmental stages. This heterogeneous group of diseases presents with distinct clinical behavior and overall prognosis. Overall, however, only a limited number of therapeutic strategies are effective for patients presenting with T-cell leukemias or lymphomas, especially following relapse. We are pleased to invite you to join this Special Issue of *Cancers* which aims at providing an up-to-date perspective over distinct targeted therapies against T-cell neoplasms, including T-ALL, T-cell lymphomas, and T-cell lymphoblastic lymphomas. In this Special Issue, original research articles, translational, clinical trials, and reviews are welcome. Research areas may include (but are not limited to) the following:

- CAR T-cells;
- Immune checkpoint inhibitors;
- Bi-specific antibodies;
- Monoclonal antibodies;
- Small molecules inhibitors;
- Molecular and cellular targets;
- Novel animal models for drug testing and developing immune and cellular-based therapies.

---

### Guest Editor

Dr. Melania Tesio

UR LIB "Lymphoma Immune biology", University Claude Bernard Lyon I,  
69376 Lyon, France

---

### Deadline for manuscript submissions

closed (30 November 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/97576](https://mdpi.com/si/97576)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)